Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature
Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim o...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2022-01, Vol.11 (3), p.739 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 739 |
container_title | Journal of clinical medicine |
container_volume | 11 |
creator | Pantic, Ivana Jevtic, Djordje Nordstrom, Charles W Madrid, Cristian Milovanovic, Tamara Dumic, Igor |
description | Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%). |
doi_str_mv | 10.3390/jcm11030739 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8836768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627676601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-97621b0516fff32ef1b7aac5e7eab34bcb5cdbd4b5ca231801470808e599e7333</originalsourceid><addsrcrecordid>eNpdkV1PHCEUhklTU4165X1D0psmdVs-ZgemFyZm40eTbWyq9pYw7JkuWwYsMGv2p_TfllFrtnJzyOHh5T28CB1R8pHzhnxamZ5SwongzSu0x4gQE8Ilf72130WHKa1IWVJWjIo3aJdPaU2oFHvoz8xZb412-Kv2toOUdbbBJxw6PIfhVzCbHIzTKVuDf-hkBmezTcf4JoLOPfh8jLVf4Kshm9ADth5_Kwqln_C9zUt86wzE0lkDnoWHu5_xKb7epAy9HkW_w9rC_fheXgKe2zziQ4QDtNNpl-Dwqe6j2_Ozm9nlZH518WV2Op-YijR50oia0ZaUgbqu4ww62gqtzRQE6JZXrWmnZtEuqlI041QSWgkiiYRp04DgnO-jk0fdu6HtYWGK9aiduou213Gjgrbq_xNvl-pnWCspeS1qWQTePwnE8HsoP6h6mww4pz2EISlWs4bUjNVVQd-9QFdhiL6MN1KiyJVYCvXhkTIxpBShezZDiRpTV1upF_rttv9n9l_G_C8l7atJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627676601</pqid></control><display><type>article</type><title>Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Pantic, Ivana ; Jevtic, Djordje ; Nordstrom, Charles W ; Madrid, Cristian ; Milovanovic, Tamara ; Dumic, Igor</creator><creatorcontrib>Pantic, Ivana ; Jevtic, Djordje ; Nordstrom, Charles W ; Madrid, Cristian ; Milovanovic, Tamara ; Dumic, Igor</creatorcontrib><description>Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%).</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11030739</identifier><identifier>PMID: 35160187</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Cardiovascular disease ; Cholangitis ; Clinical medicine ; Colorectal surgery ; Cross-sectional studies ; Diabetes ; Etiology ; Inflammation ; Inflammatory bowel disease ; Laboratories ; Neutrophils ; Pathogenesis ; Patients ; Purpura ; Review ; Steroids ; Systematic review</subject><ispartof>Journal of clinical medicine, 2022-01, Vol.11 (3), p.739</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-97621b0516fff32ef1b7aac5e7eab34bcb5cdbd4b5ca231801470808e599e7333</citedby><cites>FETCH-LOGICAL-c409t-97621b0516fff32ef1b7aac5e7eab34bcb5cdbd4b5ca231801470808e599e7333</cites><orcidid>0000-0003-3790-3951 ; 0000-0003-1137-1141 ; 0000-0002-5312-8812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836768/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836768/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35160187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pantic, Ivana</creatorcontrib><creatorcontrib>Jevtic, Djordje</creatorcontrib><creatorcontrib>Nordstrom, Charles W</creatorcontrib><creatorcontrib>Madrid, Cristian</creatorcontrib><creatorcontrib>Milovanovic, Tamara</creatorcontrib><creatorcontrib>Dumic, Igor</creatorcontrib><title>Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%).</description><subject>Antibodies</subject><subject>Cardiovascular disease</subject><subject>Cholangitis</subject><subject>Clinical medicine</subject><subject>Colorectal surgery</subject><subject>Cross-sectional studies</subject><subject>Diabetes</subject><subject>Etiology</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Laboratories</subject><subject>Neutrophils</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Purpura</subject><subject>Review</subject><subject>Steroids</subject><subject>Systematic review</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkV1PHCEUhklTU4165X1D0psmdVs-ZgemFyZm40eTbWyq9pYw7JkuWwYsMGv2p_TfllFrtnJzyOHh5T28CB1R8pHzhnxamZ5SwongzSu0x4gQE8Ilf72130WHKa1IWVJWjIo3aJdPaU2oFHvoz8xZb412-Kv2toOUdbbBJxw6PIfhVzCbHIzTKVuDf-hkBmezTcf4JoLOPfh8jLVf4Kshm9ADth5_Kwqln_C9zUt86wzE0lkDnoWHu5_xKb7epAy9HkW_w9rC_fheXgKe2zziQ4QDtNNpl-Dwqe6j2_Ozm9nlZH518WV2Op-YijR50oia0ZaUgbqu4ww62gqtzRQE6JZXrWmnZtEuqlI041QSWgkiiYRp04DgnO-jk0fdu6HtYWGK9aiduou213Gjgrbq_xNvl-pnWCspeS1qWQTePwnE8HsoP6h6mww4pz2EISlWs4bUjNVVQd-9QFdhiL6MN1KiyJVYCvXhkTIxpBShezZDiRpTV1upF_rttv9n9l_G_C8l7atJ</recordid><startdate>20220129</startdate><enddate>20220129</enddate><creator>Pantic, Ivana</creator><creator>Jevtic, Djordje</creator><creator>Nordstrom, Charles W</creator><creator>Madrid, Cristian</creator><creator>Milovanovic, Tamara</creator><creator>Dumic, Igor</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3790-3951</orcidid><orcidid>https://orcid.org/0000-0003-1137-1141</orcidid><orcidid>https://orcid.org/0000-0002-5312-8812</orcidid></search><sort><creationdate>20220129</creationdate><title>Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature</title><author>Pantic, Ivana ; Jevtic, Djordje ; Nordstrom, Charles W ; Madrid, Cristian ; Milovanovic, Tamara ; Dumic, Igor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-97621b0516fff32ef1b7aac5e7eab34bcb5cdbd4b5ca231801470808e599e7333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Cardiovascular disease</topic><topic>Cholangitis</topic><topic>Clinical medicine</topic><topic>Colorectal surgery</topic><topic>Cross-sectional studies</topic><topic>Diabetes</topic><topic>Etiology</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Laboratories</topic><topic>Neutrophils</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Purpura</topic><topic>Review</topic><topic>Steroids</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pantic, Ivana</creatorcontrib><creatorcontrib>Jevtic, Djordje</creatorcontrib><creatorcontrib>Nordstrom, Charles W</creatorcontrib><creatorcontrib>Madrid, Cristian</creatorcontrib><creatorcontrib>Milovanovic, Tamara</creatorcontrib><creatorcontrib>Dumic, Igor</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pantic, Ivana</au><au>Jevtic, Djordje</au><au>Nordstrom, Charles W</au><au>Madrid, Cristian</au><au>Milovanovic, Tamara</au><au>Dumic, Igor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-01-29</date><risdate>2022</risdate><volume>11</volume><issue>3</issue><spage>739</spage><pages>739-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%).</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35160187</pmid><doi>10.3390/jcm11030739</doi><orcidid>https://orcid.org/0000-0003-3790-3951</orcidid><orcidid>https://orcid.org/0000-0003-1137-1141</orcidid><orcidid>https://orcid.org/0000-0002-5312-8812</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2022-01, Vol.11 (3), p.739 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8836768 |
source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
subjects | Antibodies Cardiovascular disease Cholangitis Clinical medicine Colorectal surgery Cross-sectional studies Diabetes Etiology Inflammation Inflammatory bowel disease Laboratories Neutrophils Pathogenesis Patients Purpura Review Steroids Systematic review |
title | Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A58%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Manifestations%20of%20Leukocytoclastic%20Vasculitis,%20Treatment,%20and%20Outcome%20in%20Patients%20with%20Ulcerative%20Colitis:%20A%20Systematic%20Review%20of%20the%20Literature&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Pantic,%20Ivana&rft.date=2022-01-29&rft.volume=11&rft.issue=3&rft.spage=739&rft.pages=739-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11030739&rft_dat=%3Cproquest_pubme%3E2627676601%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627676601&rft_id=info:pmid/35160187&rfr_iscdi=true |